Know Cancer

or
forgot password

Cost Effectiveness Of Sunitinib Vs IFN-Alfa Or Bevacizumab + IFN-Alfa As First-Line Treatment In MRCC In Central America And The Caribbean


Phase 4
18 Years
N/A
Not Enrolling
Both
Metastatic Renal Cell Carcinoma

Thank you

Trial Information

Cost Effectiveness Of Sunitinib Vs IFN-Alfa Or Bevacizumab + IFN-Alfa As First-Line Treatment In MRCC In Central America And The Caribbean


This study was terminated on 03Feb2011 due to the fact that the anticipated number of
patients expected was not reached. The date of cessation of the drug was January 27, 2011.
There was no intervention in the treatment or administration of the drug; the study only
observed the treatment and collected data. As the study was dependent on the arrival of new
patients with metastatic renal cancer, which was of a very low incidence, the study was
terminated. Efficacy, adverse events or other safety issues were not factors in terminating
the study. Lack of patients was the only reason.


Inclusion Criteria:



- Evidence of a personally signed (or legally acceptable representative) and dated
informed consent document indicating that the subject (or a legally acceptable
representative) has been informed of all pertinent aspects of the study.

- Adult (18 years old or older) men and women with confirmed diagnosis of mRCC treated
with Sutent, IFN-α or Bevacizumab + IFN ; on the selected institutions.

Exclusion Criteria:

- Adult men or women with RCCm treated with any other medication that is not Sutent,
IFN-α or Bevacizumab + IFN.

- Adult men or women with mRCC with palliative care.

- Adult men or women with RCC without metastasis.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Rate of patients that present metastasis when consulting for first time

Outcome Time Frame:

9 months

Safety Issue:

No

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

Costa Rica: Centro de Desarrollo Estratégico e Información en Salud y Seguridad Social (CENDEISSS)

Study ID:

A6181189

NCT ID:

NCT01033981

Start Date:

May 2010

Completion Date:

February 2011

Related Keywords:

  • Metastatic Renal Cell Carcinoma
  • cost effectiveness
  • Sunitinib Central America and Caribbean Metastatic Renal Cell Carcinoma
  • Carcinoma
  • Carcinoma, Renal Cell

Name

Location